source
- Two Massachusetts biotech firms shut down, ending cancer and eye‑disease programsAdecto Pharmaceuticals, a Boston‑based biotech developing a treatment for cancers resistant to standard immunotherapy, announced it has ceased operations as of September 30. CEO Nora Minerva shared…
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…BioSpace · 1mo ago↗ source
- Novartis pays $575 million upfront for access to Chinese biotech Abogen’s RNA platform and option on ABO-2203